Literature DB >> 10728017

Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.

S R Steinhubl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10728017     DOI： 10.1023/a:1018754309025

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  23 in total

1.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Authors:  D F Kong; R M Califf; D P Miller; D J Moliterno; H D White; R A Harrington; J E Tcheng; A M Lincoff; V Hasselblad; E J Topol
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

2.  Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

Authors:  M Gawaz; A Ruf; F J Neumann; G Pogátsa-Murray; T Dickfeld; D Zohlnhöfer; A Schömig
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

3.  Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

Authors:  K Peter; M Schwarz; J Ylänne; B Kohler; M Moser; T Nordt; P Salbach; W Kübler; C Bode
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

4.  Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

Authors:  M A Mascelli; E T Lance; L Damaraju; C L Wagner; H F Weisman; R E Jordan
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

5.  Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

Authors:  S R Steinhubl; K Kottke-Marchant; D J Moliterno; M L Rosenthal; N K Godfrey; B S Coller; E J Topol; A M Lincoff
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.

Authors:  M A Mascelli; S Worley; N J Veriabo; E T Lance; S Mack; T Schaible; H F Weisman; R E Jordan
Journal:  Circulation       Date:  1997-12-02       Impact factor: 29.690

7.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

8.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

Authors:  R A Harrington; N S Kleiman; K Kottke-Marchant; A M Lincoff; J E Tcheng; K N Sigmon; D Joseph; G Rios; K Trainor; D Rose
Journal:  Am J Cardiol       Date:  1995-12-15       Impact factor: 2.778

9.  Rapid platelet-function assay: an automated and quantitative cartridge-based method.

Authors:  J W Smith; S R Steinhubl; A M Lincoff; J C Coleman; T T Lee; R S Hillman; B S Coller
Journal:  Circulation       Date:  1999-02-09       Impact factor: 29.690

10.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245
View more
  8 in total

Review 1.  Applications of anti-platelet monitoring in catheterization laboratory.

Authors:  D Mukherjee; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.

Authors:  D Mukherjee; D P Chew; M Robbins; J S Yadav; R E Raymond; D J Moliterno
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 3.  Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

Authors:  G Proimos
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 4.  Glycoprotein receptor inhibitors in the management of acute coronary syndromes.

Authors:  Henock Saint-Jacques; And Robert A Harrington
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

5.  Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.

Authors:  A C Matzdorff; G Kühnel; B Kemkes-Matthes; R Voss
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 6.  Monitoring antiplatelet therapy: What is the best method?

Authors:  D Mukherjee; D J Moliterno
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

7.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 8.  The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.

Authors:  E J Topol
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.